SCHEMBL3547293

SCHEMBL3547293

COc1ccc2cc(N3CC4CCC(C3)N4)ccc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.55
HTR1D P28221 1/20 0.55
HTR1B P28222 1/20 0.55
CHRNB2 P17787 4/20 0.45
CHRNA4 P43681 4/20 0.45
CHRNB4 P30926 3/20 0.45
CHRNA3 P32297 3/20 0.45
CYP11B1 P15538 1/20 0.42
CYP11B2 P19099 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2A6 P11509 1/20 0.41
FDFT1 P37268 1/20 0.40
HRH3 Q9Y5N1 1/20 0.39
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
MAPK1 P28482 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3546140 0.81 HTR3A (0.53) CHRNB2CHRNA4CHRNB4CHRNA3HRH3
SCHEMBL3542933 0.79 HTR1A (0.51) HTR1AHTR1DHTR1BCYP11B1CYP11B2
SCHEMBL3541006 0.78 CHRNB2 (0.45) CHRNB2CHRNA4CHRNB4CHRNA3SLC6A2
SCHEMBL22904391 0.77 HTR1A (0.52) HTR1AHTR1DHTR1BCYP11B1CYP11B2
SCHEMBL3128330 0.77 HTR1A (0.49) HTR1AHTR1DHTR1BCYP11B1CYP11B2
SCHEMBL5377695 0.76 CHRNB2 (0.61) CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL5173413 0.74 HTR1A (0.44) HTR1AHTR1DHTR1BCYP11B1CYP11B2
SCHEMBL3135941 0.74 HTR1A (0.53) HTR1AHTR1DHTR1BCYP1A2CYP2A6
SCHEMBL2249343 0.74 HTR1A (0.63) HTR1AHTR1DHTR1BCYP11B1CYP11B2
SCHEMBL6637697 0.73 HTR1A (0.94) HTR1AHTR1DHTR1BCHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7704991-B2 Substituted diazabicyclo derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2010-04-27 US claimed
US-20080280882-A1 Novel Substituted Diazabicyclo Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors NEUROSEARCH A/S (DK) 2008-11-13 US claimed
US-7704991-B2 Substituted diazabicyclo derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2010-04-27 US disclosed
US-20080280882-A1 Novel Substituted Diazabicyclo Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors NEUROSEARCH A/S (DK) 2008-11-13 US disclosed
EP-1869050-A1 NOVEL SUBSTITUTED DIAZABICYCLO DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-12-26 EP disclosed
WO-2006106090-A1 NOVEL SUBSTITUTED DIAZABICYCLO DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2006-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280882-A1 Novel Substituted Diazabicyclo Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors SLC18A2, SLC6A2, SLC6A3 HTR1A 62/4885HTR1D 183/4885HTR1B 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.